EX103

· Guangzhou Excelmab Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EX103, covering 2025-02-27 to 2025-02-27. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma [Phase 1, Phase 2]

See pricing